Cantor Fitzgerald analyst Jordan Abrams reiterates an Overweight rating on HTG Molecular Diagnostics with a $6 price target. After hosting investor meetings with management, the analyst is positive on "increased visibility into the business" with a focus on longer-term product development. Product investment positions HTG well to be the leader in RNA molecular profiling, Abrams tells investors in a research note. Meanwhile, the analyst believes the company's base profiling business "remains strong." Although biopharma partnership data readouts are the most visible potential catalysts to the shares, consistent execution in the base profiling business "will also propel the shares higher," Abrams writes.